Last reviewed · How we verify
LT3 (liothyronine) — Competitive Intelligence Brief
phase 3
Thyroid hormone replacement
Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ)
Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
LT3 (liothyronine) (LT3 (liothyronine)) — M. Medici. Liothyronine is a synthetic form of triiodothyronine (T3) that binds to thyroid hormone receptors to increase metabolic rate and cellular energy production.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LT3 (liothyronine) TARGET | LT3 (liothyronine) | M. Medici | phase 3 | Thyroid hormone replacement | Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ) | |
| Levothyroxine-Na + iodide | Levothyroxine-Na + iodide | Sanofi | marketed | Thyroid hormone replacement therapy | Thyroid hormone receptors (TR-alpha and TR-beta) | |
| Tirosint®-SOL | Tirosint®-SOL | IBSA Institut Biochimique SA | marketed | Thyroid hormone replacement | Thyroid hormone receptors (TR-alpha and TR-beta) | |
| L-T4+T3 (thyroid tablet) | L-T4+T3 (thyroid tablet) | Zhongshan Hospital Xiamen University | marketed | Thyroid hormone replacement therapy | Thyroid hormone receptors (TR-alpha, TR-beta) | |
| Levoxyl | Levothyroxine Sodium | Pfizer Inc. | marketed | Thyroid hormone replacement | Thyroid receptor proteins attached to DNA | |
| Cytomel | Liothyronine Sodium | Pfizer Inc. | marketed | Thyroid hormone replacement | Thyroid receptor proteins attached to DNA | |
| Euthyrox (levothyroxine) | Euthyrox (levothyroxine) | University Medical Center Groningen | marketed | Thyroid hormone replacement | Thyroid hormone receptors (TR-alpha and TR-beta) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Thyroid hormone replacement class)
- Pfizer Inc. · 2 drugs in this class
- Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
- IBSA Institut Biochimique SA · 1 drug in this class
- M. Medici · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
- Meyer Children's Hospital IRCCS · 1 drug in this class
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
- Oregon Health and Science University · 1 drug in this class
- Sanofi · 1 drug in this class
- Takeda · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LT3 (liothyronine) CI watch — RSS
- LT3 (liothyronine) CI watch — Atom
- LT3 (liothyronine) CI watch — JSON
- LT3 (liothyronine) alone — RSS
- Whole Thyroid hormone replacement class — RSS
Cite this brief
Drug Landscape (2026). LT3 (liothyronine) — Competitive Intelligence Brief. https://druglandscape.com/ci/lt3-liothyronine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing